Article Text

Download PDFPDF
Correlation between the use of statins and COVID-19: what do we know?
  1. Antonio Vitiello1,
  2. Raffaele La Porta2,
  3. Francesco Ferrara1
  1. 1 Pharmaceutical Department, USL 1 Umbria, Perugia, Italy
  2. 2 Clinical Pathology Department, AV1 Asur Marche, Urbino, Italy
  1. Correspondence to Dr Antonio Vitiello, Pharmaceutical Department, USL 1 Umbria, Perugia 06121, Italy; antonio.vitiello2{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The COVID-19 global pandemic caused by the new Coronavirus SARS-CoV-2 represents a challenge for the health of humanity, with few precedents. The new Coronavirus SARS-CoV-2 (COVID-19) is the cause of severe acute respiratory syndrome (SARS), a severe form of viral pneumonia.1 The virus spread rapidly from China to the rest of the world in a very short time and with considerable intensity and severity creating a ‘global emergency’. Studies have shown that angiotensin-converting enzyme 2 (ACE-2) is the entry receptor of SARS-CoV-2 into host cells. Type II pneumocytes represent 83% of the cells expressing ACE-2 in the lung. ACE-2 receptor is also expressed in extrapulmonary tissues such as heart, brain, liver and kidneys. ACE-2 is an important regulatory enzyme in the renin–angiotensin system, catalysing the2 3 conversion of …

View Full Text


  • Contributors AV: writing. FF: validation: RLP: validation.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.